11/14
09:14 am
tsha
Taysha Gene Therapies (NASDAQ:TSHA) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald.
Medium
Report
Taysha Gene Therapies (NASDAQ:TSHA) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald.
11/5
08:07 am
tsha
Taysha Gene Therapies (NASDAQ:TSHA) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $12.00 price target on the stock.
Medium
Report
Taysha Gene Therapies (NASDAQ:TSHA) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $12.00 price target on the stock.
11/5
07:39 am
tsha
Rating for TSHA
Medium
Report
Rating for TSHA
11/5
07:19 am
tsha
Taysha Gene Therapies (NASDAQ:TSHA) had its "outperform" rating reaffirmed by analysts at Citigroup Inc..
Medium
Report
Taysha Gene Therapies (NASDAQ:TSHA) had its "outperform" rating reaffirmed by analysts at Citigroup Inc..
10/21
01:40 pm
tsha
Rating for TSHA
Low
Report
Rating for TSHA
10/21
01:40 pm
tsha
Rating for TSHA
Low
Report
Rating for TSHA
10/21
08:03 am
tsha
Taysha Gene Therapies (NASDAQ:TSHA) is now covered by analysts at Raymond James Financial, Inc.. They set a "strong-buy" rating and a $13.00 price target on the stock.
Medium
Report
Taysha Gene Therapies (NASDAQ:TSHA) is now covered by analysts at Raymond James Financial, Inc.. They set a "strong-buy" rating and a $13.00 price target on the stock.
10/20
04:15 pm
tsha
Taysha Gene Therapies initiated with a Strong Buy at Raymond James
Medium
Report
Taysha Gene Therapies initiated with a Strong Buy at Raymond James
10/20
04:15 pm
tsha
Taysha Gene Therapies initiated with a Strong Buy at Raymond James
Medium
Report
Taysha Gene Therapies initiated with a Strong Buy at Raymond James
10/17
08:12 am
tsha
Taysha Gene Therapies (NASDAQ:TSHA) had its "buy" rating reaffirmed by analysts at Needham & Company LLC. They now have a $10.00 price target on the stock.
Medium
Report
Taysha Gene Therapies (NASDAQ:TSHA) had its "buy" rating reaffirmed by analysts at Needham & Company LLC. They now have a $10.00 price target on the stock.
10/17
08:12 am
tsha
Taysha Gene Therapies (NASDAQ:TSHA) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $12.00 price target on the stock.
Medium
Report
Taysha Gene Therapies (NASDAQ:TSHA) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $12.00 price target on the stock.
10/17
07:55 am
tsha
Rating for TSHA
Medium
Report
Rating for TSHA
10/17
06:35 am
tsha
Rating for TSHA
Medium
Report
Rating for TSHA
10/17
06:35 am
tsha
Rating for TSHA
Medium
Report
Rating for TSHA
10/2
01:51 pm
tsha
Rating for TSHA
Low
Report
Rating for TSHA
10/2
01:51 pm
tsha
Rating for TSHA
Low
Report
Rating for TSHA
10/2
10:50 am
tsha
Rating for TSHA
Medium
Report
Rating for TSHA
10/2
10:50 am
tsha
Rating for TSHA
Medium
Report
Rating for TSHA